Anti-Bcl2 therapy in chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 49, Issue 7, 2008, Pages 1232-1233

  Smith, Sonali ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 263; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CYTARABINE; HOMOHARRINGTONINE; IMATINIB; INTERFERON; MESSENGER RNA; OBATOCLAX; OBLIMERSEN; PROTEIN BCL 2;

CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; CYTOGENETICS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN TARGETING;

CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAXIMUM TOLERATED DOSE; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 47649126217     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802105090     Document Type: Note

References (6)

1. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H. Gattermann, N. et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355, pp. 2408-2417.
2. Wetzler, M., Donohue, K., Odenike, O., Feldman, E., Hurd, D. Stone, R. et al. Feasibility of administering Oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia - Cancer and Leukemia Group B Study 10107. Leuk Lymphoma
3. Dai, Y., Rahmani, M., Corey, S. J., Dent, P. and Grant, S. (2004) A Bcr/ Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem, 279, pp. 34227-34239.
4. Tauchi, T., Sumi, M., Nakajima, A., Sashida, G., Shimamoto, T. and Ohyashiki, K. (2003) BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res, 9, pp. 4267-4273.
5. Kim, R., Emi, M., Matsuura, K. and Tanabe, K. (2007) Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther, 14, pp. 1-11.
6. Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Skvara, H., Florian, S. Sonneck, K. et al. (2005) Identification of mcl-1 as a BCR/ ABL-dependent target in chronic myeloid leukemia (CML): Evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood, 105, pp. 3303-3311.